Expression of pERK and pAKT in pediatric high grade astrocytomas: Correlation with YKL40 and prognostic significance

Neuropathology

Volumn 32, Issue 2, 2012, Pages 133-138

  Antonelli, Manila ^a   Massimino, Maura ^c   Morra, Isabella ^d   Garrè, Maria Luisa ^e   Gardiman, Marina Paola ^f   Buttarelli, Francesca Romana ^b   Arcella, Antonietta ^g   Giangaspero, Felice ^a,g  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Department of Pathology   (Italy)

^e G GASLINI INSTITUTE   (Italy)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^g IRCCS NEUROMED   (Italy)

Author keywords

AKT; Children; High grade gliomas; MAPK; Prognosis; YKL40

Indexed keywords

GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; YKL 40 PROTEIN;

ADOLESCENT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ADIPOKINES; ADOLESCENT; ASTROCYTOMA; CHILD; CHILD, PRESCHOOL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; LECTINS; MALE; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SURVIVAL ANALYSIS;

EID: 84858958769     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2011.01252.x     Document Type: Article

References (28)

1. Norris JL, Baldwin AS Jr. Oncogenic Ras enhances NF-kappaB transcriptional activity through Raf-dependent and Raf-independent mitogen-activated protein kinase signaling pathways. J Biol Chem 1999; 14: 13841-13846.
2. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003; 12: 889-901.
3. Lakka SS, Jasti SL, Gondi C etal. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 2002; 21: 5601-5608.
4. Gupta AK, Bakanauskas VJ, Cerniglia GJ etal. The Ras radiation resistance pathway. Cancer Res 2001; 15: 4278-4282.
5. Aeder SE, Martin PM, Soh JW, Hussaini IM. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 2004; 2: 9062-9069.
6. Endersby R, Baker SJ. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008; 18: 5416-5430.
7. Faury D, Nantel A, Dunn SE etal. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007; 25: 1196-1208.
8. Pollack IF, Hamilton RL, James CD etal. Children's Oncology Group. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006; 105: 418-424.
9. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 2007; 114: 121-133.
10. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006; 65: 1181-1188.
11. Lal B, Goodwin CR, Sang Y etal. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 2009; 8: 1751-1760.
12. Custodio A, Calles A, Pérez-Segura P. Response to erlotinib in recurrent glioblastoma ultiforme showing coexpression of EGFRvIII and PTEN. Clin Transl Oncol 2010; 12: 310-314.
13. Li Y, Guessous F, DiPierro C etal. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 2009; 8: 376-385.
14. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 2002; 1: 119-126.
15. Antonelli M, Buttarelli FR, Arcella A etal. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol 2010; 99: 209-215.
16. Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 2005; 19 (3): 38.
17. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol 2011; 223: 220-230 Epub 2010 Oct 28.
18. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004; 108: 467-470.
19. Pollack IF, Hamilton RL, Burger PC etal. Children's Oncology Group. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol 2010; 99: 155-163.
20. Thorarinsdottir HK, Santi M, McCarter R etal. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 2008; 14: 3386-3394.
21. Suri V, Das P, Pathak P etal. Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro-oncol 2009; 11: 274-280.
22. Bax DA, Gaspar N, Little SE etal. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 2009; 15: 5753-5761 Erratum in: Clin Cancer Res. 2009 15:7110.
23. Griffero F, Daga A, Marubbi D etal. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 2009; 13: 7138-7148.
24. Kong DS, Song SY, Kim DH etal. Prognostic significance of c-Met expression in glioblastomas. Cancer 2009; 1: 140-148.
25. Parsons DW, Jones S, Zhang X etal. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 26: 1807-1812.
26. Pelloski CE, Mahajan A, Maor M etal. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 1: 3326-3334.
27. Zhang W, Kawanishi M, Miyake K etal. Association between YKL-40 and adult primary astrocytoma. Cancer 2010; 1: 2688-2697.
28. Paugh BS, Qu C, Jones C etal. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. Clin Oncol 2010; 28: 3061-3068.